Lumos Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 33
- Market Cap
- $31.6M
- Website
- http://www.lumos-pharma.com
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT07129759
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
- Conditions
- Growth Hormone Deficiency (GHD)
- Interventions
- Other: Matched Placebo (Capsules)
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT06948214
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT05796440
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT05250063
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Children's National Hospital, Washington, District of Columbia, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT04806854
- Locations
- 🇨🇱
Institute of Maternal and Child Research, University of Chile, Santiago, Chile
- Prev
- 1
- 2
- Next
News
Lumos Pharma's Oral LUM-201 Shows Sustained Growth in Pediatric GHD in Phase 2 Trials
Updated Phase 2 data on LUM-201 demonstrate sustained growth over 24 months in children with moderate Pediatric Growth Hormone Deficiency (PGHD).
Lumos Pharma's LUM-201 Shows Promise in Pediatric Growth Hormone Deficiency Trials
Lumos Pharma's LUM-201 met all primary and secondary endpoints in Phase 2 clinical trials, indicating its potential in treating pediatric growth hormone deficiency.